# Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

> **NCT06772623** · PHASE1,PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 252 (estimated)

## Conditions studied

- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Telisotuzumab Adizutecan
- **DRUG:** Budigalimab
- **DRUG:** Pembrolizumab
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06772623
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06772623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06772623, "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06772623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*